share_log

Conmed Analyst Ratings

Conmed Analyst Ratings

Conmed 分析师评级
Benzinga ·  2023/10/26 05:32
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/26/2023 23.96% Needham $140 → $119 Maintains Buy
07/27/2023 51.04% JP Morgan $125 → $145 Maintains Overweight
07/27/2023 45.83% Needham $139 → $140 Maintains Buy
07/27/2023 46.88% Keybanc $131 → $141 Maintains Overweight
07/24/2023 44.79% Needham → $139 Reiterates Buy → Buy
06/05/2023 44.79% Needham $135 → $139 Maintains Buy
05/22/2023 45.83% CL King → $140 Initiates Coverage On → Buy
04/27/2023 35.42% Stifel $118 → $130 Maintains Buy
04/27/2023 33.33% Piper Sandler $118 → $128 Maintains Overweight
04/27/2023 23.96% Wells Fargo $96 → $119 Maintains Equal-Weight
04/27/2023 40.63% Needham $122 → $135 Maintains Buy
04/27/2023 36.46% Keybanc $124 → $131 Maintains Overweight
03/27/2023 29.17% Keybanc → $124 Upgrades Sector Weight → Overweight
02/03/2023 22.92% Piper Sandler $108 → $118 Maintains Overweight
02/03/2023 27.08% Needham $106 → $122 Maintains Buy
11/15/2022 10.42% Needham $90 → $106 Maintains Buy
10/14/2022 -6.25% Needham $123 → $90 Maintains Buy
10/12/2022 -11.46% Jefferies → $85 Initiates Coverage On → Hold
08/02/2022 28.13% Needham $127 → $123 Maintains Buy
07/28/2022 22.92% Piper Sandler $160 → $118 Maintains Overweight
07/28/2022 32.29% Needham $155 → $127 Maintains Buy
06/23/2022 14.58% Stifel $160 → $110 Maintains Buy
05/05/2022 61.46% Needham $150 → $155 Maintains Buy
01/21/2022 56.25% Needham $158 → $150 Maintains Buy
10/28/2021 64.58% Needham $150 → $158 Maintains Buy
10/06/2021 56.25% Needham → $150 Upgrades Hold → Buy
07/15/2021 66.67% UBS → $160 Initiates Coverage On → Buy
05/25/2021 82.29% Barclays → $175 Initiates Coverage On → Overweight
04/29/2021 66.67% Piper Sandler $145 → $160 Maintains Overweight
07/30/2020 -1.04% Piper Sandler $90 → $95 Maintains Overweight
07/30/2020 4.17% Stifel $82 → $100 Maintains Buy
07/30/2020 -4.17% SVB Leerink $82 → $92 Maintains Market Perform
04/30/2020 -14.58% Stifel $65 → $82 Maintains Buy
04/23/2020 -20.83% JP Morgan $136 → $76 Maintains Overweight
11/26/2019 — Needham Downgrades Buy → Hold
11/12/2019 41.67% JP Morgan → $136 Initiates Coverage On → Overweight
10/31/2019 22.92% Stifel $99 → $118 Maintains Buy
08/22/2019 14.58% Piper Sandler $88 → $110 Upgrades Neutral → Overweight
08/01/2019 3.13% Stifel $97 → $99 Maintains Buy
04/18/2019 -1.04% Stifel → $95 Initiates Coverage On → Buy
04/15/2019 -4.17% Barclays $85 → $92 Maintains Overweight
02/19/2019 -11.46% Barclays → $85 Reinstates → Overweight
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年10月26日 23.96% 李约瑟 $140→$119 维护 买
07/27/2023 51.04% 摩根大通 $125→$145 维护 超重
07/27/2023 45.83% 李约瑟 $139→$140 维护 买
07/27/2023 46.88% KeyBanc $131→$141 维护 超重
07/24/2023 44.79% 李约瑟 →$139 重申 购买→购买
06/05/2023 44.79% 李约瑟 $135→$139 维护 买
2023年05月22日 45.83% CL国王 →$140 开始承保 →购买
04/27/2023 35.42% Stifel $118→$130 维护 买
04/27/2023 33.33% 派珀·桑德勒 $118→$128 维护 超重
04/27/2023 23.96% 富国银行 $96→$119 维护 等重
04/27/2023 40.63% 李约瑟 $122→$135 维护 买
04/27/2023 36.46% KeyBanc $124→$131 维护 超重
03/27/2023 29.17% KeyBanc →$124 升级 行业权重→超配
02/03/2023 22.92% 派珀·桑德勒 $108→$118 维护 超重
02/03/2023 27.08% 李约瑟 $106→$122 维护 买
2022年11月15日 10.42% 李约瑟 $90→$106 维护 买
10/14/2022 -6.25% 李约瑟 $123→$90 维护 买
10/12/2022 -11.46% 杰富瑞 →$85 开始承保 →保留
08/02/2022 28.13% 李约瑟 $127→$123 维护 买
07/28/2022 22.92% 派珀·桑德勒 $160→$118 维护 超重
07/28/2022 32.29% 李约瑟 $155→$127 维护 买
2022/06/23 14.58% Stifel $160→$110 维护 买
05/05/2022 61.46% 李约瑟 $150→$155 维护 买
2022年01月21日 56.25% 李约瑟 $158→$150 维护 买
10/28/2021 64.58% 李约瑟 $150→$158 维护 买
10/06/2021 56.25% 李约瑟 →$150 升级 持有→购买
07/15/2021 66.67% 瑞银集团 →$160 开始承保 →购买
2021/05/25 82.29% 巴克莱 →$175 开始承保 →超重
04/29/2021 66.67% 派珀·桑德勒 $145→$160 维护 超重
07/30/2020 -1.04% 派珀·桑德勒 $90→$95 维护 超重
07/30/2020 4.17% Stifel $82→$100 维护 买
07/30/2020 -4.17% SVB Leerink $82→$92 维护 市场表现
04/30/2020 -14.58% Stifel $65→$82 维护 买
04/23/2020 -20.83% 摩根大通 $136→$76 维护 超重
2019年11月26日 - 李约瑟 评级下调 购买→Hold
2019年11月12日 41.67% 摩根大通 →$136 开始承保 →超重
2019年10月31日 22.92% Stifel $99→$118 维护 买
2019年08月22日 14.58% 派珀·桑德勒 $88→$110 升级 中性→超重
2019年08月01日 3.13% Stifel $97→$99 维护 买
2019/04/18 -1.04% Stifel →$95 开始承保 →购买
2019年04月15日 -4.17% 巴克莱 $85→$92 维护 超重
2019年02月19日 -11.46% 巴克莱 →$85 恢复 →超重

What is the target price for Conmed (CNMD)?

康美德(CNMD)的目标价是多少？

The latest price target for Conmed (NYSE: CNMD) was reported by Needham on October 26, 2023. The analyst firm set a price target for $119.00 expecting CNMD to rise to within 12 months (a possible 23.96% upside). 16 analyst firms have reported ratings in the last year.

Needham于2023年10月26日报告了Conmed(纽约证券交易所代码：CNMD)的最新目标价。这家分析公司将目标价定为119.00美元，预计CNMD将在12个月内上涨至23.96%。过去一年，有16家分析公司公布了评级。

What is the most recent analyst rating for Conmed (CNMD)?

康美德(CNMD)的最新分析师评级是多少？

The latest analyst rating for Conmed (NYSE: CNMD) was provided by Needham, and Conmed maintained their buy rating.

Conmed(纽约证券交易所代码：CNMD)的最新分析师评级由Needham提供，Conmed维持其买入评级。

When is the next analyst rating going to be posted or updated for Conmed (CNMD)?

Conmed(CNMD)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Conmed的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Conmed的上一次评级是在2023年10月26日提交的，所以你应该预计下一次评级将在2024年10月26日左右提供。

Is the Analyst Rating Conmed (CNMD) correct?

分析师评级Conmed(CNMD)正确吗？

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $140.00 to $119.00. The current price Conmed (CNMD) is trading at is $96.00, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但康美德(Conmed)最新的评级维持不变，目标价在140.00美元至119.00美元之间。康美德(CNMD)目前的交易价格为96.00美元，超出了分析师的预测区间。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发